FKD Therapies Oy
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From FKD Therapies Oy
Having failed to live up to its promising beginnings, FerGene, the gene therapy firm founded with the backing of Ferring and Blackstone to advance the former’s candidate for bladder cancer is back under the Swiss pharma's wing. However, doubts about its future and that of nadofaragene firadonavec remain.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
The Swiss group has decided to launch FerGene with the private equity giant to give the gene therapy nadofaragene firadenovec, which has a priority review at the FDA, a better chance for a successful launch in the US.
- Gene Therapy, Cell Therapy